The clearance enables the developers to include China-based centers in an ongoing phase 1a/1b trial evaluating the agent in late-stage solid tumors. The China National Medical Products Association ...

Explore integrative therapies for metastatic prostate cancer, including nutrition, acupuncture, supplements, exercise, and ...

The use of a drug from Johnson & Johnson resulted in a lower spread of prostate cancer and reduced deaths, according to a study published on May 31. The drug Erleada—combined with therapy reducing ...

Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncology company with a BLA-directed lead asset. CAN-2409 has achieved positive Phase III results in ...

In the first-in-human TheraPb phase 1 trial, the alpha-emitting radiopharmaceutical 212Pb-ADVC001 was well tolerated at doses ...

Pfizer (PFE) announced on Thursday that its cancer drug regimen, Talzenna plus Xtandi, met the primary endpoint in a Phase 3 trial for a new indication in prostate cancer. The Phase 3 TALAPRO-3 study ...

Personalized dosing for late-stage prostate cancer treatments is critical for balancing toxicity with aggressiveness. Yet, dose-prediction models are either fast but inaccurate or accurate but too ...

Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of ...

May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and ...

J&J Prostate Cancer Drug Reduces Risk of Cancer Spread and Death in Late-Stage Study By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada ⁠used ⁠with hormone-blocking ...